Kymera Therapeutics (KYMR) Non-Current Deferred Tax Liability (2022 - 2023)
Kymera Therapeutics (KYMR) posted quarterly Non-Current Deferred Tax Liability of $68.3 million for Q4 2023, up 87.57% year-over-year from $36.4 million in Q4 2022, and up 87.57% quarter-over-quarter from $36.4 million in Q4 2022.
Kymera Therapeutics (KYMR) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $68.3 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Non-Current Deferred Tax Liability rose 87.57% year-over-year to $68.3 million; the TTM figure through Dec 2023 stood at $68.3 million (up 87.57% YoY), while the FY2023 annual figure was $68.3 million, up 87.57% from the prior year.
- Non-Current Deferred Tax Liability improved to $68.3 million in Q4 2023 per KYMR's latest filing, from $36.4 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $68.3 million in Q4 2023 and bottomed at $36.4 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 68.34 Mn |
| Dec 31, 2023 | 68.34 Mn |
| Dec 31, 2022 | 36.44 Mn |
| Dec 31, 2022 | 36.44 Mn |